CN102548573B - Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途 - Google Patents

Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途 Download PDF

Info

Publication number
CN102548573B
CN102548573B CN201080034480.3A CN201080034480A CN102548573B CN 102548573 B CN102548573 B CN 102548573B CN 201080034480 A CN201080034480 A CN 201080034480A CN 102548573 B CN102548573 B CN 102548573B
Authority
CN
China
Prior art keywords
nkg2d
antibody
diabetes
mice
mica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080034480.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102548573A (zh
Inventor
熊那
夏明灿
D·H·罗莱
J·S·彼得森
T·B·博德瓦尔斯多坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
University of California San Diego UCSD
Original Assignee
Penn State Research Foundation
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation, University of California San Diego UCSD filed Critical Penn State Research Foundation
Publication of CN102548573A publication Critical patent/CN102548573A/zh
Application granted granted Critical
Publication of CN102548573B publication Critical patent/CN102548573B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
CN201080034480.3A 2009-08-17 2010-08-16 Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途 Expired - Fee Related CN102548573B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23442509P 2009-08-17 2009-08-17
US61/234,425 2009-08-17
US30411310P 2010-02-12 2010-02-12
US61/304,113 2010-02-12
PCT/US2010/045627 WO2011022334A1 (en) 2009-08-17 2010-08-16 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes

Publications (2)

Publication Number Publication Date
CN102548573A CN102548573A (zh) 2012-07-04
CN102548573B true CN102548573B (zh) 2016-03-16

Family

ID=43014101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080034480.3A Expired - Fee Related CN102548573B (zh) 2009-08-17 2010-08-16 Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途

Country Status (11)

Country Link
US (2) US20120148581A1 (https=)
EP (1) EP2467152B1 (https=)
JP (2) JP5838158B2 (https=)
KR (1) KR20120090931A (https=)
CN (1) CN102548573B (https=)
AU (1) AU2010284428B2 (https=)
BR (1) BR112012002353A2 (https=)
CA (1) CA2769409A1 (https=)
MX (1) MX2012001999A (https=)
RU (2) RU2015138677A (https=)
WO (1) WO2011022334A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2747785A4 (en) * 2011-08-26 2015-04-15 Univ California METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION
EP2790696A1 (en) * 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
US20140235552A1 (en) * 2013-02-15 2014-08-21 Claresa Levetan Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
JP2016523264A (ja) * 2013-07-03 2016-08-08 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏに対する抗体
US20200157541A1 (en) * 2018-11-19 2020-05-21 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
US12312584B2 (en) 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158307A1 (en) * 2003-04-22 2005-07-21 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
CN1984672A (zh) * 2004-04-05 2007-06-20 加利福尼亚大学董事会 Nkg2d的调节
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004027902D1 (de) * 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158307A1 (en) * 2003-04-22 2005-07-21 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
CN1984672A (zh) * 2004-04-05 2007-06-20 加利福尼亚大学董事会 Nkg2d的调节
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection

Also Published As

Publication number Publication date
EP2467152A1 (en) 2012-06-27
AU2010284428B2 (en) 2014-09-11
JP5838158B2 (ja) 2015-12-24
RU2566264C2 (ru) 2015-10-20
AU2010284428A1 (en) 2012-02-16
EP2467152B1 (en) 2017-05-17
JP2016014030A (ja) 2016-01-28
KR20120090931A (ko) 2012-08-17
WO2011022334A1 (en) 2011-02-24
RU2012105528A (ru) 2013-09-27
CA2769409A1 (en) 2011-02-24
RU2015138677A (ru) 2018-12-25
US20120148581A1 (en) 2012-06-14
US20150376281A1 (en) 2015-12-31
MX2012001999A (es) 2012-02-29
CN102548573A (zh) 2012-07-04
JP5978362B2 (ja) 2016-08-24
JP2013502420A (ja) 2013-01-24
BR112012002353A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
CN111939261B (zh) 以il-4r抑制剂治疗嗜酸性食管炎的方法
KR102134088B1 (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
TWI772250B (zh) IL-22多肽及IL-22Fc融合蛋白質及其使用方法
US20240002488A1 (en) Method of treating or preventing liver conditions
CN102548573B (zh) Nkg2d抑制剂在治疗心血管和代谢疾病如2型糖尿病中的用途
JP6633108B2 (ja) 脂肪組織の集積を処置するための組成物および方法
CN102006887A (zh) 初原纤维形式β-淀粉样蛋白的特异性抗体
JP2022116272A (ja) Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体
UA129672C2 (uk) Антитіло до trem-1 та його застосування
WO2020023847A1 (en) Use of glucagon receptor antagonists with immunotherapeutic agent
KR20250067121A (ko) Cnx 항원-결합 분자
JP2021534195A (ja) 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置
CN102281898B (zh) Il-20拮抗剂在治疗类风湿性关节炎和骨质疏松症中的应用
WO2023230538A2 (en) Methods for the treatment of amyotrophic lateral sclerosis
CA3257359A1 (en) METHODS OF TREATING KIDNEY DISEASES OR DISORDERS
CN111886252A (zh) 促进胰岛细胞生长的方法
SG11202111742QA (en) Methods of diagnosis and treatment of rheumatoid arthritis
HK40126807A (zh) Cnx抗原结合分子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160316

Termination date: 20190816